Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 11/20 | 0.46 |
| ▸ | TP53 | P04637 | 7/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2640759 | 0.84 | LMNA (0.59) | MAPTTP53POLBS1PR1NPC1 | |
| SCHEMBL2641004 | 0.82 | NPC1 (0.52) | MAPTTP53POLBS1PR1NPC1 | |
| SCHEMBL2640808 | 0.82 | MAPT (0.52) | MAPTTP53POLBS1PR1NPC1 | |
| SCHEMBL516913 | 0.81 | MAPT (0.53) | MAPTTP53POLBS1PR1NPC1 | |
| SCHEMBL516209 | 0.81 | NPC1 (0.50) | MAPTTP53POLBS1PR1NPC1 | |
| SCHEMBL2360618 | 0.80 | NPC1 (0.65) | MAPTTP53POLBS1PR1NPC1 | |
| SCHEMBL2640833 | 0.79 | MAPT (0.45) | MAPTTP53POLBS1PR1NPC1 | |
| SCHEMBL2640845 | 0.79 | MAPT (0.49) | MAPTTP53POLBS1PR1NPC1 | |
| SCHEMBL516813 | 0.78 | ALOX5AP (0.48) | MAPTTP53POLBS1PR1NPC1 | |
| SCHEMBL2360362 | 0.77 | MAPT (0.71) | MAPTTP53POLBS1PR1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2569312-B1 | SUBSTITUTED HETEROCYCLYL BENZYL PYRAZOLES, AND USE THEREOF | BAYER IP GMBH (DE) | 2014-03-26 | — | — | EP | disclosed |
| EP-2569312-B1 | SUBSTITUTED HETEROCYCLYL BENZYL PYRAZOLES, AND USE THEREOF | BAYER IP GMBH (DE) | 2014-03-26 | — | — | EP | disclosed |
| US-20130172311-A1 | Substituted heterocyclyl benzyl pyrazoles, and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| US-20130172311-A1 | Substituted heterocyclyl benzyl pyrazoles, and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
| US-8470811-B2 | Substituted heterocyclylbenzylpyrazoles and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-25 | — | — | US | disclosed |
| US-8470811-B2 | Substituted heterocyclylbenzylpyrazoles and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-25 | — | — | US | disclosed |
| EP-2569309-A1 | HYDROXYALKYL BENZYL PYRAZOLES, AND USE THEREOF FOR THE TREATMENT OF HYPERPROLIFERATIVE AND ANGIOGENIC DISEASES | Bayer Intellectual Property GmbH (DE) | 2013-03-20 | — | — | EP | disclosed |
| EP-2569312-A1 | SUBSTITUTED HETEROCYCLYL BENZYL PYRAZOLES, AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2013-03-20 | — | — | EP | disclosed |
| US-20120028950-A1 | Substituted heterocyclylbenzylpyrazoles and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028950-A1 | Substituted heterocyclylbenzylpyrazoles and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-02 | — | — | US | disclosed |
| WO-2011141325-A1 | HYDROXYALKYL BENZYL PYRAZOLES, AND USE THEREOF FOR THE TREATMENT OF HYPERPROLIFERATIVE AND ANGIOGENIC DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011141325-A1 | HYDROXYALKYL BENZYL PYRAZOLES, AND USE THEREOF FOR THE TREATMENT OF HYPERPROLIFERATIVE AND ANGIOGENIC DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011141326-A1 | SUBSTITUTED HETEROCYCLYL BENZYL PYRAZOLES, AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011141326-A1 | SUBSTITUTED HETEROCYCLYL BENZYL PYRAZOLES, AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172311-A1 | Substituted heterocyclyl benzyl pyrazoles, and use thereof | HIF1AN, VHL, HIF1A | MAPT 4540/4885TP53 242/4885POLB 1742/4885 |
| US-20120028950-A1 | Substituted heterocyclylbenzylpyrazoles and use thereof | HIF1AN, VHL, HIF1A | MAPT 4520/4885TP53 252/4885POLB 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.